Skip to main content

New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries

View Cover

New Vaccine Development

Establishing Priorities: Volume II, Diseases of Importance in Developing Countries(1986)
Purchase Options
Purchase Options MyNAP members save 10% online. Login or Register
Overview

Contributors

Description

Common diseases cost the developing world an enormous amount in terms of human life, health, and productivity, as well as lost economic potential. New and effective vaccines could not only improve the quality of life for millions of residents in developing countries, they could also contribute substantially to further economic development. Using data from the World Health Organization and other international agencies, this book analyzes disease burdens, pathogen descriptions, geographic distribution of diseases, probable vaccine target populations, alternative control measures and treatments, and future prospects for vaccine development. New Vaccine Development provides valuable insight into immunological and international health policy priorities.

Topics

Suggested Citation

Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press.https://doi.org/10.17226/920.

Import this citation to:

Publication Info

448 pages |8.5 x 11
Paperback
ISBN: 978-0-309-03679-5
DOI: https://doi.org/10.17226/920
Contents

Table of Contents

skim chapter
Front Matter i-xvi
1. Summary 1-18
2. Priority Setting for Health-Related Investments: A Review of Methods 19-29
3. Overview of the Analytic Approach 30-43
4. Comparison of Disease Burdens 44-62
5. Predictions of Vaccine Development 63-75
6. Assessing the Likely Utilization of New Vaccines 76-81
7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines 82-105
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development 106-120
9. Findings, Conclusions, and Recommendations 121-142
Appendix A: Selection of Vaccine Candidates for Accelerated Development 143-148
Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness 149-158
Appendix C: The Burden of Disease Resulting from Diarrhea 159-169
Appendix D-1: The Prospects for Immunizing Against Dengue Virus 170-177
Appendix D-2: The Prospects for Immunizing Against Escherichia coli 178-185
Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b 186-196
Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus 197-207
Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus 208-222
Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus 223-240
Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae 241-250
Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis 251-266
Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses 267-274
Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. 275-286
Appendix D-11: The Prospects for Immunizing Against Rabies Virus 287-298
Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus 299-307
Appendix D-13: The Prospects for Immunizing Against Rotavirus 308-318
Appendix D-14: The Prospects for Immunizing Against Salmonella typhi 319-328
Appendix D-15: The Prospects for Immunizing Against Shigella spp. 329-337
Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A 338-356
Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae 357-375
Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae 376-389
Appendix D-19: The Prospects for Immunizing Against Yellow Fever 390-402
Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs 403-411
Appendix F: Technical Notes 412-412
Appendix G: Biographical Notes on Committee Members 413-417
Appendix H: Additional Sources of Advice to the Committee 418-419
Appendix I: Contents of Supplement to Volume II 420-420
Appendix J: Preface to Volume I 421-422
Appendix K: Contents to Volume I 423-423
Index 424-432
Rights

Copyright Information

The National Academies Press and the Transportation Research Board have partnered with Copyright Clearance Center to offer a variety of options for reusing our content. You may request permission to:

  • Republish or display in another publication, presentation, or other media
  • Use in print or electronic course materials and dissertations
  • Share electronically via secure intranet or extranet
  • And more

For most Academic and Educational uses no royalties will be charged although you are required to obtain a license and comply with the license terms and conditions.

Click here to obtain permission forNew Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries.

Translation and Other Rights

For information on how to request permission to translate our work and for any other rights related query please click here.

Copyright.com Customer Service

For questions about using the Copyright.com service, please contact:

Copyright Clearance Center
22 Rosewood Drive
Danvers, MA 01923
Tel (toll free): 855/239-3415 (select option 1)
E-mail: info@copyright.com
Web: https://www.copyright.com
Stats

Loading stats for New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries...